X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ALEMBIC PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ALEMBIC PHARMA DR. REDDYS LAB/
ALEMBIC PHARMA
 
P/E (TTM) x 26.1 18.0 144.6% View Chart
P/BV x 3.6 4.6 79.2% View Chart
Dividend Yield % 0.7 0.7 98.0%  

Financials

 DR. REDDYS LAB   ALEMBIC PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
ALEMBIC PHARMA
Mar-18
DR. REDDYS LAB/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788645 432.2%   
Low Rs1,902470 404.8%   
Sales per share (Unadj.) Rs860.8166.1 518.3%  
Earnings per share (Unadj.) Rs57.121.9 260.6%  
Cash flow per share (Unadj.) Rs122.027.5 443.7%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.90.7 118.9%  
Book value per share (Unadj.) Rs757.7117.8 643.4%  
Shares outstanding (eoy) m165.91188.52 88.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.73.4 81.2%   
Avg P/E ratio x41.125.5 161.4%  
P/CF ratio (eoy) x19.220.3 94.8%  
Price / Book Value ratio x3.14.7 65.4%  
Dividend payout %35.018.3 191.9%   
Avg Mkt Cap Rs m389,034105,090 370.2%   
No. of employees `00023.5NA-   
Total wages/salary Rs m32,1496,228 516.2%   
Avg. sales/employee Rs Th6,070.8NM-  
Avg. wages/employee Rs Th1,366.6NM-  
Avg. net profit/employee Rs Th402.5NM-  
INCOME DATA
Net Sales Rs m142,81031,308 456.1%  
Other income Rs m1,55270 2,207.7%   
Total revenues Rs m144,36231,378 460.1%   
Gross profit Rs m23,5126,431 365.6%  
Depreciation Rs m10,7721,055 1,021.4%   
Interest Rs m78834 2,317.6%   
Profit before tax Rs m13,5045,413 249.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m344-81 -425.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,204 363.9%   
Profit after tax Rs m9,4684,128 229.3%  
Gross profit margin %16.520.5 80.2%  
Effective tax rate %32.422.2 145.9%   
Net profit margin %6.613.2 50.3%  
BALANCE SHEET DATA
Current assets Rs m104,98418,247 575.3%   
Current liabilities Rs m68,93811,235 613.6%   
Net working cap to sales %25.222.4 112.7%  
Current ratio x1.51.6 93.8%  
Inventory Days Days7486 86.9%  
Debtors Days Days10461 168.8%  
Net fixed assets Rs m104,38520,035 521.0%   
Share capital Rs m830377 220.2%   
"Free" reserves Rs m124,88621,824 572.2%   
Net worth Rs m125,71622,201 566.3%   
Long term debt Rs m25,0895,000 501.8%   
Total assets Rs m225,44339,411 572.0%  
Interest coverage x18.1160.2 11.3%   
Debt to equity ratio x0.20.2 88.6%  
Sales to assets ratio x0.60.8 79.7%   
Return on assets %4.510.6 43.1%  
Return on equity %7.518.6 40.5%  
Return on capital %9.719.7 49.2%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m72,62314,722 493.3%   
Fx outflow Rs m18,9167,026 269.2%   
Net fx Rs m53,7077,696 697.9%   
CASH FLOW
From Operations Rs m18,0303,124 577.1%  
From Investments Rs m-14,883-8,844 168.3%  
From Financial Activity Rs m-4,4405,026 -88.3%  
Net Cashflow Rs m-1,236-693 178.3%  

Share Holding

Indian Promoters % 25.5 74.1 34.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 2.9 186.2%  
FIIs % 35.3 9.1 387.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 13.9 110.1%  
Shareholders   75,885 49,328 153.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 22, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS